Literature DB >> 24327493

Off-label drug use in a single-center pediatric cardiac intensive care unit.

Lily A Maltz1, Darren Klugman, Michael C Spaeder, David L Wessel.   

Abstract

BACKGROUND: The frequency of off-label drug use and its association with morbidity and mortality in the cardiac intensive care unit (CICU) has not been previously studied.
METHODS: Patients less than 18 years of age admitted to the CICU from June to August 2008 were retrospectively identified. Patient demographics were collected for 30 days or until CICU discharge. Off-label drug use was defined as the prescription of a medication that lacked a labeled indication based on patient's age as reported in the Micromedex drug database and electronic Physician's Desk Reference.
RESULTS: Eighty-two patients were admitted to the CICU during the study period. In all, 40 (46%) patients were male; the median age was 10.6 months. Common diagnoses were left-to-right shunt lesions (20.7%) and single-ventricle lesions (20.7%), with an overall mortality of 2.4%. Of all drugs prescribed, 36% were off-label. In all, 94% of the patients received ≥1 drug off-label. The median number of drugs prescribed off-label was four. Patients receiving more than four off-label medications were younger, had longer CICU lengths of stay (median 9.5 vs 2 days, P < .001), and increased ventilator days (median two vs one day, P < .001).
CONCLUSIONS: Off-label drug use in the CICU is common. Frequency of use is likely higher in patients with a higher severity of illness. Further safety, efficacy, and pharmaceutical trials are warranted to optimize the use of these drugs to improve outcomes.

Entities:  

Keywords:  congenital heart disease; critical care; off-label drugs; pediatrics

Mesh:

Year:  2013        PMID: 24327493     DOI: 10.1177/2150135113481042

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  6 in total

Review 1.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-07

2.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  J Am Coll Cardiol       Date:  2017-06-29       Impact factor: 24.094

Review 3.  Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review.

Authors:  Joana Magalhães; António Teixeira Rodrigues; Fátima Roque; Adolfo Figueiras; Amílcar Falcão; Maria Teresa Herdeiro
Journal:  Eur J Clin Pharmacol       Date:  2014-10-16       Impact factor: 2.953

4.  Off-Label Drug Use in Pediatric Out-Patient Care: A Multi-Center Observational Study.

Authors:  Aeshah AlAzmi; Zahra Alasmari; Consuela Yousef; Ahmed Alenazi; Mohammed AlOtaibi; Hani AlSaedi; Adnan AlShaikh; Amani AlObathani; Omaima Ahmed; Loie Goronfolah; Mousa Alahmari
Journal:  Hosp Pharm       Date:  2020-08-31

5.  Evidence of support used for drug treatments in pediatric cardiology.

Authors:  Julia Back; Håkan Wåhlander; Katarina Hanseus; Gunnar Bergman; Estelle Naumburg
Journal:  Health Sci Rep       Date:  2021-05-11

6.  Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature.

Authors:  H Christine Allen; M Connor Garbe; Julie Lees; Naila Aziz; Hala Chaaban; Jamie L Miller; Peter Johnson; Stephanie DeLeon
Journal:  J Okla State Med Assoc       Date:  2018-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.